Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia

NCT ID: NCT01350999

Last Updated: 2016-09-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 503 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2011-01-31

Brief Summary

The purpose of this study is to determine the safety and efficacy of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.

Detailed Description

TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085 contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoic acid (DHA-E)).

This is a phase 3, open-label, randomized study to evaluate the efficacy and safety of TAK-085. In addition, EPA-E is also administered for 52 weeks for reference to evaluate the safety of TAK-085 in participants with hypertriglyceridemia who are undergoing lifestyle modification.

The study period is a total of 56 weeks, comprised of a 4- week screening period and 52 weeks of treatment.

Conditions

Hypertriglyceridemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TAK-085 2 g

TAK-085 2 g, orally, once daily for up to 52 weeks.

Group Type: EXPERIMENTAL

omega-3-acid ethyl esters 90 (TAK-085)

Intervention Type: DRUG

Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

TAK-085 4 g

TAK-085 2 g, orally, twice daily for up to 52 weeks.

Group Type: EXPERIMENTAL

omega-3-acid ethyl esters 90 (TAK-085)

Intervention Type: DRUG

Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

EPA-E 1.8 g

Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.

Group Type: ACTIVE_COMPARATOR

Eicosapentaenoic acid-ethyl (EPA)

Intervention Type: DRUG

EPA-E capsules

Interventions

omega-3-acid ethyl esters 90 (TAK-085)

Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

Intervention Type: DRUG

Eicosapentaenoic acid-ethyl (EPA)

EPA-E capsules

Intervention Type: DRUG

Other Intervention Names

LOVAZA; Omacor

Eligibility Criteria

Inclusion Criteria

Visit 1 (Week -4)

1. Undergoing lifestyle modification.

2. Triglyceride (TG) level (fasting state) 150 mg/dL or higher and less than 750 mg/dL at Visit 1 (Week -4).

3. Both genders, aged from 20 to less than 75 years at the time of signing informed consent.

4. Outpatient.

5. Capable of understanding and complying with protocol requirements.

6. Signed a written, informed consent form prior to the initiation of any study procedures.

7. A female with childbearing potential (premenopausal and non-sterilized) must have agreed to use routinely adequate contraception from signing of informed consent throughout the duration of the study.

Visit 2 (Week -2)

8. Fasting TG level 150 mg/dL or higher and less than 750 mg/dL at Visit 2 (Week -2).

9. Difference in fasting low density lipoprotein-cholesterol (LDL-C) level between Visit 1 (Week -4) and Visit 2 (Week -2) within 25% of the higher value

Exclusion Criteria

Visit 1 (Week -4)

1. Any coronary artery diseases (CAD, e.g., confirmed myocardial infarction and angina pectoris) within 6 months prior to Visit 1 (Week -4) or a history of revascularization.

2. Received aortic aneurysmectomy or had had aortic aneurysm within 6 months prior to Visit 1 (Week -4).

3. History or complication of a clinically significant hemorrhagic disease (e.g., hemophilia, capillary fragility illness, digestive tract ulcer, urinary tract haemorrhage, hemoptysis, vitreous haemorrhage) within 6 months prior to Visit 1 (Week -4).

4. Diagnosed with pancreatitis.

5. Diagnosed with lipoprotein lipase (LPL) deficiency, apolipoprotein C-II deficiency or type III familial hyperlipidemia.

6. Cushing's syndrome, uremia, systemic lupus erythematosus (SLE) or serum dysproteinemia.

7. Type 1 diabetes mellitus or with uncontrolled type 2 diabetes mellitus defined by glycosylated hemoglobin (HbA1C) level of 8.0% or higher at Visit 1 (Week -4).

8. Stage III hypertension defined by systolic blood pressure of 180 mmHg or higher or diastolic blood pressure of 110 mmHg or higher regardless of the use of antihypertensive medication.

9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level at Visit 1 (Week -4) was not less than twice the upper limit of the normal reference range.

10. If female, was pregnant or lactating.

11. Habitual drinking defined by an average daily alcohol intake of 100 mL or more , drug abuse or drug dependency, or a history of any of these conditions.

12. Started to take any antihyperlipidemic drugs within 4 weeks prior to Visit 1 (Week -4).

13. Received any investigational products (including those for post-marketing clinical study) within 12 weeks prior to Visit 1 (Week -4).

14. Received TAK-085 in a clinical study.

15. Judged as being ineligible for study participation by the investigator or subinvestigator for any other reasons.

Visit 2 (Week -2)

16. ALT or AST level at Visit 2 (Week -2) was twice the upper limit of the normal reference range or higher.

17. Needed a change in the dose of antihyperlipidemic drugs or antidiabetic drugs, addition of a new drug or a change in the type of the drugs during the screening period.

18. Judged as being ineligible for study participation by the investigator or subinvestigator for any other reasons.

Visit 3 (Week 0)

19. Needed a change in the dose of antihyperlipidemic drugs or antidiabetic drugs, addition of a new drug or a change in the type of the drugs during the screening period.

20. Judged as being ineligible for study participation by the investigator or subinvestigator for any other reasons

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Associate Professor, Clinical Cell Biology and Medicine

Role: STUDY_DIRECTOR

Graduate School of Medicine, Chiba University

Other Identifiers

JapicCTI-090936

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1120-7892

Identifier Type: REGISTRY

Identifier Source: secondary_id

JapicCTI-R140451

Identifier Type: REGISTRY

Identifier Source: secondary_id

TAK-085/OCT-001

Identifier Type: -

Identifier Source: org_study_id